Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
-
+
EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Presentations: 108
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP08.01-073 - AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC
Author(s): Rajiv Kumar- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Presentations: 171
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP08.02-012 - Real-world Analysis of the Efficacy and Safety of lorlatinib in Patients with ALK-Positive Non-small Cell Lung Cancer in Korea
Author(s): Beung-chul AHN- Abstract
Loading...
-
+
P1.11 - Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy
- Type: Regular Poster
- Track: Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy
- Presentations: 2
- Coordinates: 8/07/2022, 17:00 - 19:00, Exhibit Hall - Hall B
-
+
P1.11-01 - Cobolimab With Dostarlimab and Docetaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung
Author(s): Hye Ryun Kim- Abstract
Loading...
-
+
OA12 - Novel and Combination Strategies for SCLC
- Type: Oral
- Track: Small Cell Lung Cancer and Neuro-Endocrine Tumors
- Presentations: 10
- Moderators:Alessandra Curioni-Fontecedro
- Coordinates: 8/08/2022, 16:00 - 17:00, Hall C8
-
+
OA12.06 - First-Line Pembrolizumab or Placebo Combined With Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results
16:32 - 16:42 | Author(s): Charles M Rudin
- Abstract
Loading...